In a variety of preclinical models of hematological malignancies, STAT3 deficiency in NK cells improves tumor surveillance, recommending that STAT3 inhibitors could trigger the NK cells-induced cytotoxicity against leukemia (28). This evidence concerns the gene STAT3 and neoplasm.